Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants
Menée à partir de données protéomiques et génomiques portant sur 29 266 patients atteints d'un cancer du poumon et 56 450 témoins d'ascendance européenne, cette étude identifie 10 protéines plasmatiques associées au risque de cancer du poumon
Background : Plasma proteins are potential biomarkers for complex diseases. We aimed to identify plasma protein biomarkers for lung cancer.
Methods : We investigated genetically predicted plasma levels of 1130 proteins in association with lung cancer risk among 29,266 cases and 56,450 controls of European descent. For proteins significantly associated with lung cancer risk, we evaluated associations of genetically predicted expression of their coding genes with the risk of lung cancer.
Results : Nine proteins were identified with genetically predicted plasma levels significantly associated with overall lung cancer risk at a false discovery rate (FDR) of <0.05. Proteins C2, MICA, AIF1, and CTSH were associated with increased lung cancer risk, while proteins SFTPB, HLA-DQA2, MICB, NRP1, and GMFG were associated with decreased lung cancer risk. Stratified analyses by histological types revealed the cross-subtype consistency of these nine associations and identified an additional protein, ICAM5, significantly associated with lung adenocarcinoma risk (FDR < 0.05). Coding genes of NRP1 and ICAM5 proteins are located at two loci that have never been reported by previous GWAS. Genetically predicted blood levels of genes C2, AIF1, and CTSH were associated with lung cancer risk, in directions consistent with those shown in protein-level analyses.
Conclusion : Identification of novel plasma protein biomarkers provided new insights into the biology of lung cancer.
British Journal of Cancer , résumé, 2023